

Alison Gulbis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9906202/publications.pdf>

Version: 2024-02-01

36
papers

1,075
citations

623734

14
h-index

552781

26
g-index

36
all docs

36
docs citations

36
times ranked

2002
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 1 clinical trial using mblL21 ex vivo "expanded donor-derived NK cells after haploidentical transplantation. <i>Blood</i> , 2017, 130, 1857-1868.	1.4	256
2	Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 45-63.	27.6	178
3	Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type. <i>Haematologica</i> , 2010, 95, 1183-1190.	3.5	152
4	Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2013, 88, 301-305.	4.1	81
5	Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. <i>Cancer</i> , 2016, 122, 2680-2688.	4.1	48
6	Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1914-1920.	2.0	46
7	High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphoid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1677-1686.	2.0	43
8	Prevention of Cytomegalovirus Reactivation in Haploidentical Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 353-358.	2.0	43
9	Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 909-913.	2.0	39
10	BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. <i>Blood</i> , 2014, 124, 2306-2312.	1.4	35
11	Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 939-946.	2.4	32
12	Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis. <i>Leukemia and Lymphoma</i> , 2015, 56, 711-715.	1.3	21
13	High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. <i>Lancet Haematology</i> , 2017, 4, e283-e292.	4.6	19
14	Evaluation and Management of BK Virus-Associated Nephropathy Following Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1589-1593.	2.0	18
15	Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1602-1609.	2.0	15
16	Modified CVAD and modified CBAD compared to high-dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2017, 98, 388-392.	2.2	12
17	Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. <i>Haematologica</i> , 2022, 107, 899-908.	3.5	9
18	The Emerging Role of Gemcitabine in Conditioning Regimens for Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1382-1389.	2.0	6

#	ARTICLE	IF	CITATIONS
19	Feasibility and Implementation of a Multimodal Supportive Care Program to Improve Outcomes in Older Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 1008-1014.	1.2	5
20	The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. <i>Journal of Oncology Pharmacy Practice</i> , 2014, 20, 257-262.	0.9	4
21	A case series using famciclovir in stem cell transplant recipients with valganciclovir hypersensitivity reactions. <i>Journal of Oncology Pharmacy Practice</i> , 2015, 21, 305-309.	0.9	4
22	A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan±clofarabine in allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 0, , .	2.4	3
23	Characterizing human herpes virus 6 following hematopoietic stem cell transplantation. <i>Journal of Oncology Pharmacy Practice</i> , 2015, 21, 85-92.	0.9	2
24	Use of argatroban and catheter-directed thrombolysis with alteplase in an oncology patient with heparin-induced thrombocytopenia with thrombosis. <i>American Journal of Health-System Pharmacy</i> , 2014, 71, 711-716.	1.0	1
25	Allogeneic stem cell transplantation (AlloSCT) for patients (pts) with acute leukemia following venetoclax-based therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7047-7047.	1.6	1
26	Polyoma (BK) Viruria Prior to Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) from Donors Other Than Matched Siblings: A Prospective Evaluation of Hemorrhagic Cystitis (HC) Incidence. <i>Blood</i> , 2008, 112, 50-50.	1.4	1
27	Durable Responses with Ipilimumab Plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. <i>Blood</i> , 2018, 132, 4585-4585.	1.4	1
28	High-Dose Chemotherapy Regimens. , 2019, , 37-57.		0
29	Does Polyoma (BK) Virus Contribute to Development of Hemorrhagic Cystitis (HC) in Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation (UD HSCT) Recipients? A Prospective Evaluation.. <i>Blood</i> , 2006, 108, 5282-5282.	1.4	0
30	Durability Results of Non-Myeloablative (NMA) Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed Follicular Lymphoma: 17- Year Experience. <i>Blood</i> , 2018, 132, 4651-4651.	1.4	0
31	Influence of the Intensity of the Conditioning Regimens on the Risks of Gvhd in Patients Receiving Rituximab Prophylaxis during Allogeneic Stem Cell Transplantation (alloSCT). <i>Blood</i> , 2018, 132, 4584-4584.	1.4	0
32	Allogeneic stem cell transplantation (AlloSCT) for patients (pts) with lymphoma and chronic lymphocytic leukemia (CLL) following targeted small molecules inhibitors (SMIs).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7550-7550.	1.6	0
33	Clinical Relevance of MYC/BCL2 and Cell of Origin in Patients with Relapsed Diffuse Large B-Cell Lymphoma Treated with Autologous Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 2021-2021.	1.4	0
34	Post-Transplant Cyclophosphamide (PT-Cy) Based Haploidentical Cell Transplantation (Haplo) Versus Rabbit Anti-Thymocyte Globulin (r-ATG) Based HLA Matched Unrelated Donor (MUD) Transplantation in Patients (pts) with Relapsed/Refractory Lymphoma. <i>Blood</i> , 2019, 134, 4530-4530.	1.4	0
35	Nonmyeloablative Allogeneic Transplantation (NMAT) Confers an Overall Survival Benefit with Similar Non-Relapse Mortality When Compared to Autologous Stem Transplantation (ASCT) for Patients (pts) with Relapsed Follicular Lymphoma (FL). <i>Blood</i> , 2019, 134, 322-322.	1.4	0
36	<i>Bacterial Prophylaxis in Patients with Acute Gvhd; Who Is at Risk for Bloodstream Infections?</i>. <i>Blood</i> , 2021, 138, 2870-2870.	1.4	0